16th International Conference on Neonatology and Pediatrics

  • 26-27 Apr 2021
  • Online Event

Description

The 16th International Conference on Neonatology and Pediatrics covers topics such as:

  • Neonatology and Perinatology
  • General Pediatrics and Adolescent Medicine
  • Pediatric Anesthesia, and Otorhinolaryngology
  • Allergy, Immunology, and Rheumatology
  • Developmental and Behavioural Problems
  • Dermatology and Ophthalmology
  • Pediatric Cardiology, and Pericarditis
  • Emergency Medicine, and Pediatric Surgery
  • Endocrinology and Growth
  • Neurology, and Neurodevelopmental Disorders
  • Pediatric Genetics and Radiology
  • Gastroenterology, Hepatology, and Nutrition
  • Probiotics: Baby and functional food
  • Hematology and Oncology
  • Nephrology and Urology
  • Infectious Diseases and Immunizations
  • Pulmonology
  • Psychology and Bipolar disorders
  • Pediatric Clinical Trials in Drug Development
  • Pediatric and Neonatal Care Nursing
  • Rare diseases in childhood and their impact on families
  • Environmental and Social Pediatrics

The 16th International Conference on Neonatology and Pediatrics brings together senior attendees with job titles such as:

  • Researchers
  • Pediatricians
  • Associations and Societies
  • Nurses
  • Medical Colleges
  • Pediatric Faculty
  • Data Management Companies
  • Pediatric Physicians
  • Software developing companies
  • Training Institutes
  • Manufacturing Medical Devices Companies
  • Business Entrepreneurs
  • Case Managers
  • Residents
  • Physician Assistants
  • Young researchers
  • Hospital General Counsel
  • Hospital Administrators

Past Events

Important

Please, check "International Conference on Neonatology and Pediatrics" official website for possible changes, before making any traveling arrangements

Event Categories

Health & Medicine: Healthcare, Pediatrics

Other Events with Similar Categories

Other Events with Similar Location or Organizer

Featured Conferences & Exhibitions

Articles / News / Press releases

Article content. Press on the above link to close

Sana Barakat1, Saba Elgendi2, Amal Mahfouz1, Abeer Hassan1

Institute(s):

1Alexandria University, Faculty of Medicine, Pediatrics, Alexandria, Egypt, 2Alexandria University, Faculty of Medicine, Pathology, Alexandria, Egypt

Objectives and Study: With increasing prevalence of clarithromycin and metronidazole resistant H. pylori strains, eradication rates with triple therapy have fallen below 80% worldwide. Unlike that to clarithromycin or metronidazole, H.pylori resistance to amoxicillin(AMO) remains uncommon. AMO is also unique in that its bactericidal effect against H. pylori is time dependent (6-8 h after administration) and can be amplified by increasing the maximum intragastric pH(>6.5) using high-dose proton pump inhibitor( PPI) .we aimed to  evaluate the efficacy and safety of high and frequent doses of PPI-AMO dual therapy for H. pylori eradication as a first- line therapy in children in Egypt where resistance rates for clarithromycin and metronidazole are relatively high. 

Methods: 
One hundred and fifty six children with H pylori infection ,2-14 years ,( 80 boys ) were randomly assigned to one of two regimens: 1-dual therapy with amoxicillin (50mg/kg/day) and omeprazole (3mg/kg/day) three time daily for 2 weeks. 2- triple therapy with with amoxicillin(50mg/kg/day), metronidazole (20 mg/kg/day) and omeprazole (1mg/kg/day) twice daily for 2 weeks. Both groups are comparable as regard demographic , clinical and endoscopic data. H. pylori status was determined by rapid urease test and histopathology before treatment and by stool Ag 4 weeks after cessation of any medication.

Results: 
One hundred and forty three children completed the study. The eradication rate was 80.5%  58/72 in dual therapy group (intention-to-treat {ITT} analysis: 74.3%) vs. 84.7% 61/72 in triple therapy group ( ITT analysis 78.2%) these differences were not significant .Side effects ( diarrhea, nausea, abdominal discomfort and headache) , were more frequently recorded in triple therapy group 27/71( 38%) than dual therapy group 16/62 ( 25.8% )dual therapy group ( p< 0.05).None of the patients stopped taking medication because of the side effects.

Conclusions: 
High-dose PPI-amoxicillin dual therapy is comparable to the stander triple therapy for H. pylori eradication in children, however , it had fewer side effects . Dual therapy my provide an acceptable alternative first line therapy for H.pylori eradication in children in Egypt where high resistance rates to clarithromycin and metronidazole had been reported.

This study has been registered at Pan African Clinical Trials Registry ,Cochrane South Africa, under identifier PACTR201807134057681.